- Joined
- Jul 13, 2010
- Messages
- 1,972
This is interesting and counterintuitive. I havent seen this one posted yet.
The research team studied 755 male patients at Intermountain Healthcare hospitals. The men were between the ages of 58 and 78, and all had severe coronary artery disease. They were split into three different groups, which received varied doses of testosterone administered either by injection or gel.
The medium-dose group achieved normal levels - up to 742 ng/dl, while the high-dose group had levels over 742 ng/dl. The conclusions:
After one year, 64 patients who weren’t taking testosterone supplements suffered major adverse cardiovascular events, while only 12 who were taking medium doses of testosterone and nine who were taking high doses did.
After three years, 125 non-testosterone-therapy patients suffered major adverse cardiovascular events, while only 38 medium-dose and 22 high-dose patients did.
After three years, 99 patients who weren’t taking testosterone supplements had died, while only 25 medium-dose and 9 high-dose did.
This is one of the first studies that compares medium-dose to high-dose TRT. High-dose TRT was able to reduce death by 400% compared to no TRT and by 200% compared to medium-dose TRT over a 3 year time period in people with heart disease. Up to date there hasn't been a single drug that has produced better results in a clinical trial.
The research team studied 755 male patients at Intermountain Healthcare hospitals. The men were between the ages of 58 and 78, and all had severe coronary artery disease. They were split into three different groups, which received varied doses of testosterone administered either by injection or gel.
The medium-dose group achieved normal levels - up to 742 ng/dl, while the high-dose group had levels over 742 ng/dl. The conclusions:
After one year, 64 patients who weren’t taking testosterone supplements suffered major adverse cardiovascular events, while only 12 who were taking medium doses of testosterone and nine who were taking high doses did.
After three years, 125 non-testosterone-therapy patients suffered major adverse cardiovascular events, while only 38 medium-dose and 22 high-dose patients did.
After three years, 99 patients who weren’t taking testosterone supplements had died, while only 25 medium-dose and 9 high-dose did.
This is one of the first studies that compares medium-dose to high-dose TRT. High-dose TRT was able to reduce death by 400% compared to no TRT and by 200% compared to medium-dose TRT over a 3 year time period in people with heart disease. Up to date there hasn't been a single drug that has produced better results in a clinical trial.